{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29751792", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29751792, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper reports that the SLC29A3 S158F (c.473C > T, rs780668) genotype CT/TT is associated with increased overall survival compared to the CC genotype, but it does not mention any significant association for genotypes GT + TT compared to GG for overall survival in the context of gemcitabine treatment in non-small cell lung cancer. Therefore, the claim that GT + TT are not associated with overall survival compared to GG is supported by the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMID 29751792), what p-value was reported for this association?", "answer": "= 0.080", "response": "The reported p-value for the association of rs2231142 (ABCG2 Q141K) with progression-free survival in non-small cell lung carcinoma patients treated with gemcitabine was adjusted *P* = 0.007."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "39811327", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 39811327, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMID 39811327), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "The confidence interval reported for HLA-A*31:03 in the context of Stevens-Johnson Syndrome (SJS) was 0.13\u20130.27."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26555147", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26555147, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMID 26555147), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no significant association between rs2298771 (SCN1A c.3184A>G) and carbamazepine metabolism, and thus no specific p-value for this association was highlighted in the results."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25278709", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25278709, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMID 25278709), what OR was reported?", "answer": "7.9", "response": "The reported odds ratio (OR) for the association of the rs8099917 G allele with null-response to peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin in Hepatitis C virus infection was 7.9."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "32695297", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 32695297, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper reports that the MTHFR rs1801133 TT genotype is associated with higher plasma methotrexate levels compared to the CC genotype, indicating that the alleles do have an association with methotrexate concentrations."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMID 32695297), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported a p-value of <0.05 for the association between the MTHFR rs1801131 AC genotype and decreased hepatic toxicity in the context of methotrexate treatment in acute lymphoblastic leukemia."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True"}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24498053", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24498053, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMID 24498053)?", "answer": 619, "response": "619 controls were included in the study of rs13242038 and heroin."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28727815", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28727815, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMID 28727815), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study reported no significant differences for rs776746 (*CYP3A5*1* carriers) in relation to everolimus concentrations, but it did not specify a p-value for this association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28045923", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28045923, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an \"Allele A\" and \"Allele G\" in relation to response to bevacizumab in women with breast neoplasms. The study discusses various SNPs and their associations with pathologic complete response (pCR) to bevacizumab, but it does not specify alleles in the manner described in the claim. Therefore, based on the information provided in the paper, the claim cannot be directly evaluated as supported or contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMID 28045923)?", "answer": 33, "response": "The paper does not mention rs17577 specifically. Therefore, there is no information provided about the number of controls included in the study of rs17577 and bevacizumab in breast neoplasms."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False"}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "990860", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 990860, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not specifically mention trimethoprim in relation to G6PD deficiency and hemolysis. It discusses primaquine, nitrofurantoin, aspirin, and sulphamethoxazole. Therefore, the claim about trimethoprim is neither supported nor contradicted by this paper. However, based on the information provided, the claim is not addressed, so it cannot be evaluated as supported or contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMID 990860)?", "answer": 8, "response": "The study in PMID 990860 does not include any cases specifically related to G6PD deficiency and trimethoprim. The paper does not mention trimethoprim in its investigation of drug-induced hemolysis in G6PD deficiency."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20362271", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20362271, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMID 20362271), what OR was reported?", "answer": "1.0834", "response": "The reported odds ratio (OR) for rs2542151 in the study was 1.0834 for the non-Hispanic European ancestry group and 1.0446 for the non-Hispanic European + unknown ancestry group."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000010", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28255319", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28255319, is the following pharmacogenomic claim supported or contradicted: Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not specifically mention genotypes AG, GG, or AA in relation to increased platelet reactivity when treated with aspirin and clopidogrel. The study focuses on the association of CYP2C19*2, CYP2C19*17, and P2Y12 polymorphisms with platelet reactivity and clinical outcomes. Therefore, the claim regarding genotypes AG, GG, and AA is not addressed in this paper, and thus it cannot be determined as supported or contradicted based on the provided study."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2046934 and aspirin, clopidogrel in Efficacy (PMID 28255319), what confidence interval was reported?", "answer": "1.64\u20133.53", "response": "The study does not report a specific confidence interval for the association of rs2046934 with aspirin and clopidogrel efficacy. The paper discusses the association of P2Y12 polymorphisms, including rs2046934, with clinical outcomes and platelet reactivity, but it does not provide a specific confidence interval for this SNP in relation to aspirin and clopidogrel efficacy."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "The paper does not provide a specific confidence interval for the odds ratio (OR) related to rs2046934 and aspirin, clopidogrel efficacy. Therefore, it is not possible to determine whether the confidence interval for the OR excludes the null value of 1.0 based on the information provided in the study. Thus, the answer is false."}]}
{"chain_id": "chain_000011", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29318894", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29318894, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an allele T versus allele C comparison in relation to tacrolimus trough concentrations. The study focused on validating 44 SNPs associated with tacrolimus trough concentrations, and only variants in CYP3A4 and CYP3A5 were significantly associated. Without specific information on the alleles T and C in the context of this study, it is not possible to determine if the claim is supported or contradicted. Therefore, the claim cannot be evaluated based on the information provided in the paper."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs10264272 and tacrolimus in Disease:Kidney Transplantation, Disease:Transplantation (PMID 29318894), what p-value was reported for this association?", "answer": "= 0.269", "response": "The p-value reported for the association of rs10264272 with tacrolimus in the context of Kidney Transplantation and Transplantation was 0.269."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000012", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "24141364", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 24141364, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3824662 and asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine in Disease:Acute lymphoblastic leukemia (PMID 24141364), what p-value was reported for this association?", "answer": "= 0.039", "response": "The paper does not report a specific p-value for the association of rs3824662 with the treatment involving asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, and vincristine in acute lymphoblastic leukemia. The p-values reported in the study are related to the association of rs3824662 with Ph-like ALL and not specifically with the treatment response to the mentioned drugs."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000013", "chain_family": "B_claim\u2192presence_absence", "pmid": "34158603", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34158603, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 34158603, rs74569896 is associated with Efficacy, Toxicity, Metabolism/PK outcomes for aspirin, clopidogrel. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not_reported. The paper discusses the association of rs74569896 with major adverse cardiovascular events (MACE) in patients treated with clopidogrel and aspirin, but it does not specifically address the association of rs74569896 with efficacy, toxicity, or metabolism/pharmacokinetic (PK) outcomes for aspirin or clopidogrel."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 34158603 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 34158603 reports quantitative statistics for the association of rs74569896 with major adverse cardiovascular events (MACE). In the discovery stage, the odds ratio (OR) is 2.87 with a 95% confidence interval (CI) of 1.51\u20135.45 and a p-value of 3.87 \u00d7 10^\u22123. In the replication stage, the hazard ratio (HR) is 1.90 with a 95% CI of 1.39\u20132.61 and a p-value of 5.91 \u00d7 10^\u22125. The meta-analysis p-value is 1.31 \u00d7 10^\u22126."}]}
{"chain_id": "chain_000014", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28696411", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28696411, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs6313 and risperidone in Other:Schizophrenia (PMID 28696411), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association of rs6313 with risperidone response in schizophrenia was 0.447."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000015", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23809542", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23809542, is the following pharmacogenomic claim supported or contradicted: CYP2C19 *17 is not associated with post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2C19*17 and clopidogrel in Efficacy (PMID 23809542), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of CYP2C19*17 with post-treatment ADP-stimulated platelet aggregation, after adjusting for the CYP2C19*2 variant, was 0.69."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "False."}]}
{"chain_id": "chain_000016", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27247849", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27247849, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of cognitive dysfunction due to opioids in people with Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs2160652 and opioids in Disease:Neoplasms (PMID 27247849)?", "answer": 98, "response": "The study included 202 cases in the discovery sample and 98 cases in the validation sample for the analysis of rs2160652 and opioids in patients with neoplasms."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000017", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3778151 and heroin in Toxicity (PMID 25744370), what p-value was reported for this association?", "answer": "= 3E-3", "response": "The p-value reported for the association of rs3778151 with heroin addiction in the study was 2.4\u00d710^-7."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000018", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29706892", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29706892, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with severity of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper does not report a significant association between the STAT-3 rs1053004 polymorphism (allele C) and the severity of neutropenia in patients treated with FOLFIRI (fluorouracil, irinotecan, and leucovorin) for colorectal cancer. The significant findings related to allele C were associated with gastrointestinal toxicity, not neutropenia."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2972164 and fluorouracil, irinotecan, leucovorin in Disease:Colorectal Neoplasms (PMID 29706892), what OR was reported?", "answer": "1.34", "response": "For the study of rs2972164 in the context of fluorouracil, irinotecan, and leucovorin treatment for colorectal neoplasms, the reported odds ratio (OR) was 0.36 with a 95% confidence interval (CI) of 0.16\u20130.82 in the discovery cohort."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000019", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20031608", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20031608, is the following pharmacogenomic claim supported or contradicted: Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1051375 and verapamil in Disease:Coronary Artery Disease (PMID 20031608), what confidence interval was reported?", "answer": "1.67\u201312.67", "response": "The confidence interval reported for the rs1051375 G/G genotype associated with an increased risk of the primary outcome when treated with verapamil was OR 4.59, 95% CI 1.67-12.67."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000020", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "20665488", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 20665488, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs9394992 and gemcitabine in Disease:Pancreatic Neoplasms (PMID 20665488), what HR was reported?", "answer": "1.08", "response": "The hazard ratio (HR) reported for rs9394992 (hENT1 C913T) in relation to progression-free survival in pancreatic neoplasms was 1.08 (95% CI: 0.74-1.57)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the HR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000021", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "22850190", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22850190, is the following pharmacogenomic claim supported or contradicted: Allele T is not associated with risk of Hypersensitivity when treated with sulfamethoxazole / trimethoprim in people with Infection. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs77005399 and sulfamethoxazole / trimethoprim in Disease:Infectious disease (PMID 22850190)?", "answer": 99, "response": "Ninety-nine cases were included in the study of rs77005399 and sulfamethoxazole/trimethoprim in infectious disease."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000022", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23963862", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23963862, is the following pharmacogenomic claim supported or contradicted: Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs139887 and carboplatin, docetaxel, paclitaxel in Disease:Ovarian Neoplasms (PMID 23963862), what OR was reported?", "answer": "1.77", "response": "The reported odds ratio (OR) for rs139887 in the study was 1.77."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000023", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "35457347", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 35457347, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1800497 and methylphenidate in Other:Attention Deficit Disorder with Hyperactivity, Other:Fetal Alcohol Syndrome (PMID 35457347)?", "answer": 114, "response": "The study included 114 cases for the analysis of rs1800497 and methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000024", "chain_family": "B_claim\u2192presence_absence", "pmid": "36833383", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 36833383, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 36833383, rs4149056 is associated with PD, Metabolism/PK outcomes for atorvastatin, simvastatin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "contradicted"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 36833383 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 36833383 reports quantitative statistics for the association between rs4149056 and outcomes related to atorvastatin and simvastatin. Specifically, it provides odds ratios (OR) and confidence intervals (CI) for dose change and any change in drug use (discontinuation or switch) for both simvastatin and atorvastatin users. For example, the paper reports an adjusted OR of 0.42 (95% CI 0.15\u20131.16) for dose change in simvastatin users with the TC/CC genotype compared to the TT genotype."}]}
{"chain_id": "chain_000025", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper discusses the association of the rs1799971 SNP, where the A allele is not significantly associated with heroin addiction on its own. Instead, the A allele is associated with increased risk of heroin addiction only in the presence of the rs3778150-C allele. The paper does not support a direct association of the A allele with increased risk compared to the G allele without considering the context of other SNPs."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical_association evidence. The study investigates the association between specific genetic variants and heroin addiction in human populations, which is characteristic of clinical association studies."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3823010 and heroin in Toxicity (PMID 25744370), what confidence interval was reported?", "answer": "1.1\u20131.37", "response": "For the study of rs3823010 and heroin addiction, the reported confidence interval for the odds ratio in the meta-analysis was 1.23 (1.10-1.37)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval for the odds ratio (1.10-1.37) excludes the null value of 1.0."}]}
{"chain_id": "chain_000026", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "26729753", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26729753, is the following pharmacogenomic claim supported or contradicted: Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs201279313 and atenolol, hydrochlorothiazide, metoprolol in Disease:Hypertension (PMID 26729753), what p-value was reported for this association?", "answer": "= 1.10E-07", "response": "The p-value reported for the association of rs201279313 with blood pressure response to atenolol, hydrochlorothiazide, and metoprolol in the meta-analysis was 2.5*10^-8."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000027", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40281622", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40281622, is the following pharmacogenomic claim supported or contradicted: Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs4149056 and atorvastatin in Other:Cardiovascular Disease, Other:Diabetes Mellitus, Other:Acute coronary syndrome, Other:Dyslipidaemia (PMID 40281622), what OR was reported?", "answer": "2.202", "response": "The reported odds ratio (OR) for the association of the *SLCO1B1 rs4149056* variant with statin-associated muscle symptoms (SAMS) among atorvastatin users was 2.202."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000028", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "38673067", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 38673067, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs717620 and mycophenolic acid, tacrolimus in Other:Kidney Transplantation (PMID 38673067), what p-value was reported for this association?", "answer": "= 0.038", "response": "The reported p-value for the association of rs717620 (ABCC2 -24C>T) with mycophenolic acid and tacrolimus in kidney transplantation was 0.038."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000029", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "34910759", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34910759, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs10485058 and methadone in Other:Opioid-Related Disorders (PMID 34910759)?", "answer": 1165, "response": "The study included 1,165 cases in the analysis of rs10485058 and methadone dose in individuals with Opioid-Related Disorders."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000030", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "33285053", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 33285053, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3786362 and capecitabine in Other:Colorectal Neoplasms (PMID 33285053), what OR was reported?", "answer": "0.38", "response": "The reported odds ratio (OR) for rs3786362 in relation to capecitabine-induced hand-foot syndrome was 0.38 (95% CI, 0.21 to 0.70)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000031", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "29097388", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 29097388, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs35123024 and atenolol, hydrochlorothiazide in Disease:Hypertension (PMID 29097388), what OR was reported?", "answer": "3.71", "response": "The odds ratio (OR) reported for the variant rs35123024 near OR5H14 associated with uncontrolled blood pressure on combination therapy with atenolol and hydrochlorothiazide was 3.71, with a 95% confidence interval of 2.13\u20136.45, and a P-value of 3.46E-06 in the PEAR study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000032", "chain_family": "B_claim\u2192presence_absence", "pmid": "27977335", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27977335, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 27977335, rs3766246 is associated with Toxicity outcomes for morphine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is supported. The paper reports that the *FAAH* variant rs3766246 is associated with morphine-related adverse outcomes, specifically with the hypercapnic ventilatory response (HCVR), which is an indicator of morphine-induced respiratory depression, a toxicity outcome."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 27977335 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 27977335 reports a p-value for the association of rs3766246 with the hypercapnic ventilatory response (HCVR). The p-value is reported as <0.0001, indicating a highly significant association."}]}
{"chain_id": "chain_000033", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "37198710", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 37198710, is the following pharmacogenomic claim supported or contradicted: Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1045642 and tacrolimus in Other:Kidney Transplantation (PMID 37198710), what p-value was reported for this association?", "answer": "= 0.01", "response": "The p-value reported for the association of rs1045642 (C3435T) with acute rejection in kidney transplantation was 0.008 for the CC genotype, 0.001 for the CT genotype, and 0.01 for the C allele when compared to the non-acute rejection group."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000034", "chain_family": "B_claim\u2192presence_absence", "pmid": "16476706", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 16476706, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 16476706, rs671531 is associated with Toxicity outcomes for heroin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 16476706 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 16476706 does not report any quantitative statistic for the claim regarding rs671531 and toxicity outcomes for heroin."}]}
{"chain_id": "chain_000035", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "23860526", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 23860526, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with response to cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2010963 and cyclophosphamide in Disease:Prostatic Neoplasms (PMID 23860526), what p-value was reported for this association?", "answer": "= 0.0485", "response": "The reported p-value for the association between rs2010963 (\u2212634G/C) and response to cyclophosphamide in Prostatic Neoplasms was 0.0485."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000036", "chain_family": "B_claim\u2192presence_absence", "pmid": "26607661", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 26607661, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 26607661, SLCO1B1*1, SLCO1B1*15 is associated with Toxicity outcomes for enalapril. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 26607661 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 26607661 reports quantitative statistics for the association between SLCO1B1*15 and enalapril-induced cough. For example, the risk of enalapril-induced cough was nearly 7-fold higher in patients carrying the *15/*15 haplotype pairs compared to the reference haplotype *1b/*1b, with an odds ratio (OR) of 6.94 and a 95% confidence interval (CI) of 1.30\u201337.07, and a p-value of 0.020."}]}
{"chain_id": "chain_000037", "chain_family": "B_claim\u2192presence_absence", "pmid": "34512362", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 34512362, is the following pharmacogenomic claim supported, contradicted, or not reported: Genotypes CT + TT is associated with decreased concentrations of atorvastatin in men as compared to genotype CC. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 34512362 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 34512362 does not report any quantitative statistic for this claim."}]}
{"chain_id": "chain_000038", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "28790841", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 28790841, is the following pharmacogenomic claim supported or contradicted: UGT1A1 *6 + *28 is not associated with increased likelihood of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that UGT1A1 *6/*28 variants were not significantly associated with severe neutropenia in lung cancer patients administered a low dose of CPT-11, and there was no significant association between UGT1A1 mutations and severe hematologic toxicity, including neutropenia, in colorectal cancer patients."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of UGT1A1*1, UGT1A1*6, UGT1A1*28 and irinotecan in Other:Colorectal Neoplasms, Other:Lung Neoplasms (PMID 28790841), what p-value was reported for this association?", "answer": "= 0.7", "response": "The study reported a p-value of 0.042 for the association between the UGT1A1*6 mutant genotype and the increased risk of severe delayed diarrhea in colorectal cancer patients when administered a CPT-11 dose \u2265130 mg/m\u00b2. However, for the association with neutropenia, the study did not report a significant p-value, indicating no significant association."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True"}]}
{"chain_id": "chain_000039", "chain_family": "B_claim\u2192presence_absence", "pmid": "22162992", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 22162992, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 22162992, rs1045642 is associated with Toxicity, Metabolism/PK outcomes for olanzapine. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "not_reported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 22162992 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "No, PMID 22162992 does not report any quantitative statistic for the claim regarding rs1045642 and its association with toxicity, metabolism/PK outcomes for olanzapine."}]}
{"chain_id": "chain_000040", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "18007983", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 18007983, is the following pharmacogenomic claim supported or contradicted: HLA-B *44:02 + *44:03 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene. Answer one of: supported, contradicted.", "answer": "contradicted", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of HLA-B*44:02, HLA-B*44:03 and trichloroethylene in Toxicity (PMID 18007983)?", "answer": 113, "response": "There were 113 cases included in the study of HLA-B*44:02, HLA-B*44:03, and trichloroethylene in toxicity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000041", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31066027", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31066027, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:01 and carbamazepine in Toxicity (PMID 31066027), what confidence interval was reported?", "answer": "2.47\u201323.67", "response": "The confidence interval reported for the association of HLA-A*31:01 with carbamazepine-induced drug-induced liver injury (DILI) was 95% CI 2.47\u201323.67."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000042", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40405401", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40405401, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs3787728 and doxorubicin in Other:Hepatocellular Carcinoma (PMID 40405401), what p-value was reported for this association?", "answer": "= 0.045", "response": "The p-value reported for the association of rs3787728 with overall survival (OS) was 0.04, and for progression-free survival (PFS), it was 0.054."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000043", "chain_family": "B_claim\u2192presence_absence", "pmid": "38707740", "num_turns": 2, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 38707740, is the following pharmacogenomic claim supported, contradicted, or not reported: In PMID 38707740, UGT1A1*1, UGT1A1*6, UGT1A1*28 is associated with Dosage, Efficacy outcomes for fluorouracil, irinotecan, leucovorin. Answer one of: supported, contradicted, not_reported.", "answer": "not_reported", "response": "The claim is not reported. The paper focuses on the association of UGT1A1*6 and UGT1A1*28 polymorphisms with adverse events, specifically neutropenia and leukopenia, during treatment with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin, but it does not address dosage or efficacy outcomes."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "Does PMID 38707740 report any quantitative statistic (p-value/OR/CI) for this claim?", "answer": "no", "response": "Yes, PMID 38707740 reports several quantitative statistics related to the association of UGT1A1*6 and UGT1A1*28 polymorphisms with adverse events. For example, the paper reports p-values for the association of the UGT1A1*6 or *28 (+/+) genotype with decreased white blood cell count (p=0.009) and decreased neutrophil count (p=0.017). However, these statistics are related to adverse events, not dosage or efficacy outcomes."}]}
{"chain_id": "chain_000044", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "40741000", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 40741000, is the following pharmacogenomic claim supported or contradicted: Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "The paper does not provide specific information about an \"Allele A\" or \"Allele C\" in relation to increased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with neoplasms. The paper discusses various genetic variants associated with anthracycline-induced cardiotoxicity, but without specific reference to alleles labeled as \"A\" or \"C\". Therefore, based on the information provided in the paper, the claim cannot be directly assessed as supported or contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs17583889 and daunorubicin, doxorubicin in Other:Neoplasms (PMID 40741000), what OR was reported?", "answer": "1.84", "response": "The study reported an odds ratio (OR) of 1.84 for the variant rs17583889 in relation to anthracycline-induced cardiotoxicity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000045", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "25744370", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 25744370, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs511435 and heroin in Toxicity (PMID 25744370), what OR was reported?", "answer": "1.2", "response": "The reported odds ratio (OR) for rs511435 in association with heroin addiction was 1.16 (95% CI: 1.05-1.29) in the meta-analysis across all cohorts."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000046", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "31090079", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 31090079, is the following pharmacogenomic claim supported or contradicted: Allele C is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs1801253 and atenolol, metoprolol in Other:Tachycardia (PMID 31090079)?", "answer": 459, "response": "The study does not specify the number of cases specifically for rs1801253 in individuals with tachycardia. The analysis was conducted on broader cohorts from the PEAR, PEAR-2, and INVEST studies, which included participants with hypertension."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000047", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "8971426", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 8971426, is the following pharmacogenomic claim supported or contradicted: CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of CYP2D6*1, CYP2D6*2, CYP2D6*17 and debrisoquine in Metabolism/PK (PMID 8971426), what p-value was reported for this association?", "answer": "< 0.001", "response": "The paper does not report a specific p-value for the association between CYP2D6*1, CYP2D6*2, CYP2D6*17, and debrisoquine metabolism."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": true, "response": "The paper does not provide a specific p-value for the association, so it is not possible to determine whether the association would remain significant at alpha = 0.01. Therefore, the answer is false."}]}
{"chain_id": "chain_000048", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "27566582", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 27566582, is the following pharmacogenomic claim supported or contradicted: Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is contradicted. The paper does not provide evidence that allele C is associated with increased concentrations of methotrexate compared to allele T. Instead, it discusses various SNPs and their associations with methotrexate pharmacokinetics and toxicity, but does not specifically support the claim regarding allele C and increased methotrexate concentrations."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical_association evidence."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of rs9282564 and methotrexate in Metabolism/PK (PMID 27566582)?", "answer": 59, "response": "The study included 59 patients in the analysis of rs9282564 and methotrexate metabolism/pharmacokinetics."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": true, "response": "True."}]}
{"chain_id": "chain_000049", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmid": "39974498", "num_turns": 4, "model": "gpt-4o", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMID 39974498, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "Contradicted."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs121918623 and antiepileptics in Other:Epilepsy (PMID 39974498), what p-value was reported for this association?", "answer": "= 1", "response": "The p-value reported for the association between rs121918623 and antiepileptics in epilepsy was 1.00."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
